<DOC>
	<DOCNO>NCT01213446</DOCNO>
	<brief_summary>This open-label study investigate pharmacokinetics ( PK ) , efficacy , safety von Willebrand Factor/Factor VIII ( VWF/FVIII ) , Biostate , child Von Willebrand disease ( VWD ) treatment VWF product require prophylactic therapy , haemostatic control surgery , control non-surgical , spontaneous , traumatic bleeding event .</brief_summary>
	<brief_title>Study BiostateÂ® Children With Von Willebrand Disease</brief_title>
	<detailed_description />
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<criteria>Male female subject 0 &lt; 12 year age Diagnosed VWD Type 1 , 2A , 3 Desmopressin acetate ( DDAVP ) treatment ineffective , contraindicate , available subject von Willebrand factor : ristocetin cofactor ( VWF : RCo ) &lt; 20 % screen subject history VWF : RCo &lt; 10 % Evidence vaccination hepatitis A B presence antibody hepatitis A B due either previous infection prior immunization Written inform consent give Active bleed immediately prior initial PK period Received treatment DDAVP VWF concentrate product VWD 5 day prior first study treatment Have receive aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) within 7 day commence PK period . Known history suspicion VWF FVIII inhibitor Acute chronic medical condition , VWD , may affect conduct study Known suspect hypersensitivity previous evidence severe side effect FVIII/VWF concentrate Participation clinical study use investigational compound another study 3 month precede study start Unwillingness and/or inability comply study requirement</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Von Willebrand Disease</keyword>
</DOC>